ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)
Status:
Recruiting
Trial end date:
2025-02-01
Target enrollment:
Participant gender:
Summary
A Global, Phase 2 Study of ARX788 in HER2-positive, Metastatic Breast Cancer Patients whose
Disease is Resistant or Refractory to T-DM1, and/or T-DXd, and/or Tucatinib-containing
Regimens